The HIV drug, Ritonavir, is a competitive inhibitor of HIV protease. One of the challenges of treating HIV is its high mutation rate, which can create resistance to available drugs. Where in the protease enzyme would amino acid changes need to take place in order to make it ineffective?

Question

BlackTom AI · Accepted Answer

To understand where amino acid changes could render Ritonavir ineffective, we first consider how competitive inhibitors work: they bind to the active site of an enzyme, blocking substrate access. 
Option 1 proposes mutations at an allosteric site. While allosteric mutations can affect enzyme activity or inhibitor binding in some cases, Ritonavir is designed to fit the active site of HIV protease, so resistance most commonly arises from changes near the active site that directly impact inhibitor binding or substrate processing rather than distant allosteric regions. 
Option 2 asserts mutations in or near the active site. This is consistent with the mechanism of competitive inhibition: alterations here can reduce inhibitor affinity or restore substrate processing despite the presence of the drug, leading to resistance. Such changes often preserve the enzyme’s overall function while hindering inhibitor binding. 
Option 3 mentions a cofactor binding site. HIV protease is a dimeric protease that does not rely on a separate, classic cofactor for catalysis in the same way many enzymes do; thus, mutations at a cofactor site would be less directly tied to overcoming a competitive inhibitor like Ritonavir. 
Option 4 suggests mutations in regions that determine packaging into the virus capsid. Those regions relate to assembly and packaging, not the catalytic action or inhibitor binding of the protease, so this would be an unlikely route to confer resistance to a protease inhibitor. 
Option 5 states that such mutations could occur anywhere with equal probability. In reality, resistance tends to arise where it most directly impacts drug binding or substrate turnover; random global mutations across the protein are far less efficient at conferring resistance than targeted changes near the active site. 
Overall, the most plausible and widely observed mechanism of resistance for a competitive protease inhibitor like Ritonavir involves alterations in or near the active site that reduce inhibitor binding while maintaining catalytic function.

The HIV drug, Ritonavir, is a competitive inhibitor of HIV protease. One of the challenges of treating HIV is its high mutation rate, which can create resistance to available drugs. Where in the protease enzyme would amino acid changes need to take place in order to make it ineffective?Single choice

Similar Questions

Which statement is TRUE regarding the active sites of enzymes?

There were three catalytic triad residues shown (Ser-His-Asp). Which additional residue was shown? The protein backbone at that location is able to make valuable H-bond contacts with the transition state that forms.

Which one of the follwing statements describes best the common features of enzyme active sites?

The region of an enzyme into which the substrate fits is a:

Choose a, b, c or d as the best answer.2. Which statement would the author, most probably, agree with?

More Practical Tools for Students Powered by AI Study Helper

Homework AI Solver

Stylized AI Paper Writer

Plagiarism Checker Assistant

Citation AI Academic Writing Tool

In-Class Translation Assistant

AI Note Generator

AI Quiz Answers

Past Exam Questions from University Test Bank

Smart Practice Assistant

Adaptive Practice

Making Your Study Simpler